Founder and CEO, Alltyr, Inc.
Psychiatry
Dr. Mark L. Willenbring, MD
|
|
Give Review
Dr. Mark L. Willenbring is an expert in the field of Psychiatry. He researched medicine at University of Minnesota Medical School. University of Minnesota Medical School has a rank of 40 in research and a 10 in primary care He has 17 awards "CMS Meaningful Use Stage 1 Certification", "Marty Mann Founder", "Certificate for Outstanding Contributions", "NIH Directors", "Emmy Award to NIAAA", "Outstanding Category", "Distinguished Technical Communication", "Excellence", "Distinguished Fellow", "Life Member", "Network Directors Award for Excellence", "Sabbatical", "Best paper presented", "Best Paper", "GEICO Federal Public Service Award for Alcoholism Prevention and Treatment", "Best Doctors in America" and "Guide to Americas Top Psychiatrists". Mark Willenbring is a published doctor. He has 62 papers published. The most current publication "Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure." He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Chronic care management programme is no more effective than usual primary care at increasing abstinence among people with Alcohol or substance dependency.
- Relapse in alcohol use Disorder.
- Commentary on Derringer et al. (2013): More evidence for a unidimensional framework for substance use Disorders.
- Significant reductions in drinking following brief Alcohol treatment provided in a hepatitis C clinic.
- Helping patients who drink too much: an evidence-based guide for primary care clinicians.
- Expanding the role of health services research as a tool to reduce the public health burden of alcohol use Disorders.
- Are medications that reduce risk of drinking or heavy drinking, or that promote abstinence, of value in the treatment of Alcohol dependence?
- Outcomes of a Hepatitis C screening program at a large urban VA medical center.
- Medications to treat Alcohol dependence: adding to the continuum of care.
- Symptom-driven lorazepam protocol for treatment of severe Alcohol withdrawal delirium in the intensive care unit.
- Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes.
- The COMBINE Study-: An Overview of the Largest Pharmacotherapy Study to Date for Treating Alcohol Dependence.
- Course of recovery from Alcoholism.
- Promoting repeat tobacco Dependence treatment: are relapsed smokers interested?
- Addressing substance Abuse in health care settings.
- Advances in the pharmacotherapy of Alcoholism: challenging misconceptions.
- Organizational change in management of hepatitis C: evaluation of a CME program.
- Challenges and opportunities for medications development in Alcoholism: an international perspective on collaborations between academia and industry.
- A randomized trial of concurrent versus delayed smoking intervention for patients in Alcohol dependence treatment.
- Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C.
- Use of Alcohol Screening and Brief Interventions
in Primary Care Settings:Implementation and Barriers. - Beliefs about evidence-based practices in Addiction treatment: a survey of Veterans Administration program leaders.
- A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.
- Timing of Alcohol and smoking cessation (TASC): smoking among substance use patients screened and enrolled in a clinical trial.
- Timing of Alcohol and smoking cessation study.
- Spectrum of disease in U.S. veteran patients with hepatitis C.
- Integrating hepatitis prevention services into a substance use Disorder clinic.
- Ethnic differences in Alcohol treatment outcomes and the effect of concurrent smoking cessation treatment.
- A broader view of change in drinking behavior.
- Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review.
- Barriers to the care of persons with dual diagnoses: organizational and financing issues.
- Amoxapine and amitriptyline in the outpatient treatment of endogenous Depression.
- Integrating qualitative and quantitative components in evaluation of case management.
- Organic mental Disorders associated with heavy drinking and alcohol dependence.
- Alcohol use in volunteers 1 year after a study requiring Alcohol intake.
- Alcoholism screening in the elderly.
- Measurement of depression in Alcoholics.
- Differences in cerebral asymmetries related to drinking history and ethnicity. A computerized axial tomography (CAT) scan study.
- Adrenocortical hyperactivity in newly admitted Alcoholics: prevalence, course and associated variables.
- Sexual dysfunction and psychological diStress in methadone maintenance.
- Thyrotropin and prolactin response to thyrotropin-releasing hormone in depressed and nondepressed Alcoholic men.
- Integrated outpatients treatment for medically ill Alcoholic men: results from a quasi-experimental study.
- Case management applications in substance use Disorders.
- A comparison of the Alcohol Dependence Scale and clinical diagnosis of Alcohol dependence in male medical outpatients.
- Characteristics of male medical patients referred for Alcoholism treatment.
- The use of Alcohol home delivery services by male problem drinkers: a preliminary report.
- A clinical tool for rating response to civil commitment for substance Abuse treatment.
- Prevention and Treatment of Hypertension Study (PATHS): effects of an Alcohol treatment program on blood pressure.
- A randomized trial of integrated outpatient treatment for medically ill Alcoholic men.
- Alcohol home delivery services: a source of Alcohol for underage drinkers.
- Randomized trial of an intervention to facilitate recycling for relapsed smokers.
- Variations in evidence-based clinical practices in nine United States Veterans Administration Opioid agonist therapy clinics.
- Factors associated with readiness to stop smoking among patients in treatment for alcohol use Disorder.
- Psychiatric illness among Drug court probationers.
- Beneficial effects of treatment of nicotine Dependence during an inpatient substance abuse treatment program.
- Psychoneuroendocrine effects of methadone maintenance.
- Improving the quality of VA care for patients with substance-use Disorders: the Quality Enhancement Research Initiative (QUERI) substance abuse module.
- Psychiatric care management for chronic addictive Disorders: conceptual framework.
- Application of case management to Drug abuse treatment: overview of models and research issues.
- The impact of depressive symptoms on Alcohol and cigarette consumption following treatment for Alcohol and nicotine dependence.
- Integrating care for patients with infectious, psychiatric, and substance use Disorders: concepts and approaches.
Schools
University Of Minnesota Medical School
St Paul Ramsey Med Center
University Calif Davis
University Of Wisconsin Madison
University Of Minnesota
Procedures Preformed
- Alcohol Testing
- Detoxification
- Drug Testing
- Electroconvulsive Therapy (ECT)
- View All
Conditions Treated
- Addiction
- Adjustment Disorder
- Alcoholism (Alcohol Dependence)
- Amphetamine and Other Psychostimulant Dependence
- View All
Doctors Specialties
- Addiction Psychiatry
- Forensic Psychiatry
- Psychiatry
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Marty Mann Founder
- Certificate for Outstanding Contributions
- NIH Director’s
- Emmy Award to NIAAA
- Outstanding Category
- Distinguished Technical Communication
- Excellence
- Distinguished Fellow
- Life Member
- Network Director’s Award for Excellence
- Sabbatical
- Best paper presented
- Best Paper
- GEICO Federal Public Service Award for Alcoholism Prevention and Treatment
- Best Doctors in America
- Guide to America’s Top Psychiatrists
Education
-
University of Wisconsin -
University of California Davis -
University of Minnesota Medical School -
University of Minnesota
Drug Facts
| NPI NUMBER | 1003930124 | |
| NPPES Provider LastName | WILLENBRING | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 551022564 | |
| NPPES Provider State | MN | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 969.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 173.0 | |
| Percent Opioid Claims | 17.85 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1003930124 |
| Last Name Of The Provider | WILLENBRING |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
Dr. Thomas J. Keul, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carrie M. Borchardt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John C. Kluznik, MD |
|
|
Dr. Mary Beth Lardizabal, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria Del Rosario Grau, MD |
|
|
Dr. William D. Spring Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bradley J. Dupre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth A. Canepa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christina H. Frazel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce H. Field, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brianna A. Murugesan, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Janet A. Zander, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David G. Einzig, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen K. Dickson, MD |
|
|
Dr. Keith E. Hartman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas G. Gratzer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Svetlana J. Simovic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John R. Stroemer, MD |
|
|
Kaying Vang |